<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04985734</url>
  </required_header>
  <id_info>
    <org_study_id>EDGE1850</org_study_id>
    <nct_id>NCT04985734</nct_id>
  </id_info>
  <brief_title>Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Patients With Idiopathic Peripheral Neuropathy</brief_title>
  <official_title>Study on the Occurrence of Transthyretin Amyloidosis Cardiomyopathy in Patients With Idiopathic Peripheral Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the present study is to determine the occurrence of wild-type and hereditary&#xD;
      transthyretin amyloidosis cardiomyopathy among patients with the diagnosis of idiopathic&#xD;
      peripheral neuropathy in the setting of a state-of-the-art diagnostic work-up; the&#xD;
      investigators believe that the identification of patients with ATTR-CM in this setting can&#xD;
      contribute to the early diagnosis of a largely underrecognized condition and, therefore,&#xD;
      offer conditions to timely initiation of appropriate therapy with impact on prognosis of&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background. Different studies have described the value of amyloidosis screening in different&#xD;
      clinical settings. The investigators hypothesize that in a relevant yet undetermined&#xD;
      proportion of patients with idiopathic peripheral neuropathy a concomitant diagnosis of&#xD;
      transthyretin amyloidosis cardiomyopathy can be made with a modern diagnostic work-up based&#xD;
      on Technetium-scintigraphy as the primary screening tool. Further the investigators believe&#xD;
      that the identification of these patients can lead to early initiation of therapy and&#xD;
      modification of the prognosis of the disease.&#xD;
&#xD;
      Objective. To study the occurrence of transthyretin amyloidosis cardiomyopathy in patients&#xD;
      with a diagnosis of idiopathic peripheral neuropathy using Tc-scinfigraphy as the primary&#xD;
      screening tool.&#xD;
&#xD;
      Methods. This will be a prospective longitudinal cohort of adult patients with the diagnosis&#xD;
      of idiopathic peripheral neuropathy. All patients will be submitted to a cardiologic&#xD;
      evaluation that will include clinical evaluation, laboratory tests, electrocardiogram and&#xD;
      echocardiography. For the diagnosis of amyloidosis all patients will be submitted to&#xD;
      99mTc-Methyl-Diphosphonate scintigraphy. Those with a positive result (grade 2 to 3 cardiac&#xD;
      uptake) will be considered as having diagnosis of transthyretin amyloidosis cardiomyopathy&#xD;
      and will be further submitted to genetic testing for transthyretin mutation; patients with&#xD;
      abnormal scintigraphic results that do not meet current semi-quantitative diagnostic criteria&#xD;
      will be submitted to additional investigation, that will include magnetic resonance heart&#xD;
      imaging and fat biopsy. All patients will receive standard care for heart failure and&#xD;
      transthyretin amyloidosis cardiomyopathy and will be follow-up every 6 months with clinical&#xD;
      parameters, quality life questionnaire, ergospirometer and echocardiogram Perspectives. The&#xD;
      investigators believe that the identification of patients with transthyretin amyloidosis&#xD;
      cardiomyopathy in this setting can contribute to the early diagnosis of a largely&#xD;
      underrecognized condition and, therefore, offer conditions to timely initiate appropriate&#xD;
      therapy with impact on prognosis of patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Cohort of patients</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnosis yield</measure>
    <time_frame>1 year</time_frame>
    <description>Diagnosis yield of Tc-scintigraphy as a screening tool for ATTR-CM, as measured by the percentage of patients with a confirmed diagnosis of ATTR-CM in relation to the whole population of patients studied</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Amyloidosis Cardiac</condition>
  <condition>Amyloid Polyneuropathy</condition>
  <condition>Amyloidosis</condition>
  <condition>Heart Failure</condition>
  <condition>Cardiomyopathy Non-Dilated</condition>
  <condition>Cardiomyopathies, Secondary</condition>
  <arm_group>
    <arm_group_label>Patients under diagnostic work-up</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Specific diagnostic work-up for ATTR-CM patients</intervention_name>
    <description>Technetium-scintigraphy</description>
    <arm_group_label>Patients under diagnostic work-up</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        - Adult patients (&gt; 18 years old) with diagnosis of idiopathic peripheral neuropathy&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Patients with alternative established diagnosis of heart disease (ischemic heart&#xD;
             disease, primary valvular heart disease, cardiomyopathies, pericardial disease)&#xD;
&#xD;
          -  Patients with end stage renal disease undergoing dialysis&#xD;
&#xD;
          -  Patients with other medical conditions recognized to impair the 1-year prognosis of&#xD;
             patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Emeline van Craenenbroek</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Victor S Issa</last_name>
      <email>victorsarli.issa@uza.br</email>
    </contact>
    <investigator>
      <last_name>Emelin Van Craenenbroek, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 17, 2021</study_first_submitted>
  <study_first_submitted_qc>July 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyloidosis Cardiac</keyword>
  <keyword>Amyloid Polyneuropathy</keyword>
  <keyword>Amyloidosis</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Amyloid Neuropathies</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

